[go: up one dir, main page]

GT200900168A - Nueva utilizacion terapeutica para el tratamiento de las leucemias - Google Patents

Nueva utilizacion terapeutica para el tratamiento de las leucemias

Info

Publication number
GT200900168A
GT200900168A GT200900168A GT200900168A GT200900168A GT 200900168 A GT200900168 A GT 200900168A GT 200900168 A GT200900168 A GT 200900168A GT 200900168 A GT200900168 A GT 200900168A GT 200900168 A GT200900168 A GT 200900168A
Authority
GT
Guatemala
Prior art keywords
leukemies
treatment
therapeutic use
new therapeutic
cancerose
Prior art date
Application number
GT200900168A
Other languages
English (en)
Inventor
Bernad Bourrie
Pierre Casellas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38268928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900168(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900168A publication Critical patent/GT200900168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL TRATAMIENTO DE LAS LEUCEMIAS, QUE ES UNA ENFERMEDAD CANCEROSA DE LA MEDULA OSEA Y DE LA SANGRE UTILIZANDO COMPUESTOS N-[2-(2,1,3-BENZOTIADIAZOL-5-ILAMINO)-6-(2,6-DICLOROFENIL)PIRIDO[2,3-D]PIRIMIDIN-7-IL]-N'-(1,1-DIMETILETIL)-UREA.
GT200900168A 2006-12-28 2009-06-16 Nueva utilizacion terapeutica para el tratamiento de las leucemias GT200900168A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0611492A FR2910813B1 (fr) 2006-12-28 2006-12-28 Nouvelle utilisation therapeutique pour le traitement des leucemies

Publications (1)

Publication Number Publication Date
GT200900168A true GT200900168A (es) 2010-03-19

Family

ID=38268928

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900168A GT200900168A (es) 2006-12-28 2009-06-16 Nueva utilizacion terapeutica para el tratamiento de las leucemias

Country Status (39)

Country Link
US (1) US8236811B2 (es)
EP (1) EP2107906B1 (es)
JP (1) JP5317987B2 (es)
KR (1) KR101458233B1 (es)
CN (1) CN101568338B (es)
AR (1) AR064550A1 (es)
AT (1) ATE534392T1 (es)
AU (1) AU2007347370B2 (es)
BR (1) BRPI0720963A2 (es)
CA (1) CA2672716C (es)
CL (1) CL2007003846A1 (es)
CO (1) CO6190610A2 (es)
CR (1) CR10881A (es)
CY (1) CY1112443T1 (es)
DK (1) DK2107906T3 (es)
EA (1) EA016873B1 (es)
EC (1) ECSP099449A (es)
ES (1) ES2377843T3 (es)
FR (1) FR2910813B1 (es)
GT (1) GT200900168A (es)
HR (1) HRP20120170T1 (es)
JO (1) JO2748B1 (es)
MA (1) MA31100B1 (es)
MX (1) MX2009007054A (es)
MY (1) MY148515A (es)
NI (1) NI200900129A (es)
NO (1) NO20092496L (es)
NZ (1) NZ577991A (es)
PE (1) PE20081548A1 (es)
PL (1) PL2107906T3 (es)
PT (1) PT2107906E (es)
RS (1) RS52162B (es)
SI (1) SI2107906T1 (es)
SV (1) SV2009003315A (es)
TN (1) TN2009000234A1 (es)
TW (1) TWI433678B (es)
UA (1) UA97505C2 (es)
WO (1) WO2008102075A2 (es)
ZA (1) ZA200904478B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
EP2638911A1 (en) * 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
ES2745983T3 (es) * 2013-12-13 2020-03-04 Novartis Ag Formas de dosificación farmacéutica
US20230136218A1 (en) * 2019-09-23 2023-05-04 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
ATE190978T1 (de) 1994-11-14 2000-04-15 Warner Lambert Co 6-aryl-pyrido(2,3-d)pyrimidine und -naphthyridine zur hemmung der durch protein-tyrosin-kinase hervorgerufenen zellvermehrung
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
CN1395578A (zh) * 2000-01-25 2003-02-05 沃尼尔·朗伯公司 吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂
YU66502A (sh) 2000-03-06 2005-09-19 Warner-Lambert Company 5-alkilpirido(2,3-d)pirimidini, inhibitori tirozinkinaza
CA2417942C (en) 2000-08-04 2010-06-29 Warner-Lambert Company 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Also Published As

Publication number Publication date
MY148515A (en) 2013-04-30
EA016873B1 (ru) 2012-08-30
JP5317987B2 (ja) 2013-10-16
JP2010514743A (ja) 2010-05-06
AU2007347370B2 (en) 2013-05-23
US8236811B2 (en) 2012-08-07
NI200900129A (es) 2011-12-13
AU2007347370A1 (en) 2008-08-28
TW200833343A (en) 2008-08-16
NZ577991A (en) 2012-01-12
CR10881A (es) 2009-08-12
CN101568338B (zh) 2011-11-23
WO2008102075A2 (fr) 2008-08-28
MA31100B1 (fr) 2010-01-04
KR101458233B1 (ko) 2014-11-04
CO6190610A2 (es) 2010-08-19
ZA200904478B (en) 2010-08-25
ATE534392T1 (de) 2011-12-15
MX2009007054A (es) 2009-08-12
US20090298790A1 (en) 2009-12-03
DK2107906T3 (da) 2012-03-19
CY1112443T1 (el) 2015-12-09
PL2107906T3 (pl) 2012-04-30
TWI433678B (zh) 2014-04-11
SV2009003315A (es) 2010-02-05
EA200970639A1 (ru) 2010-04-30
EP2107906A2 (fr) 2009-10-14
ES2377843T3 (es) 2012-04-02
FR2910813B1 (fr) 2009-02-06
KR20090103899A (ko) 2009-10-01
PE20081548A1 (es) 2009-01-04
CN101568338A (zh) 2009-10-28
EP2107906B1 (fr) 2011-11-23
UA97505C2 (ru) 2012-02-27
JO2748B1 (en) 2014-03-15
BRPI0720963A2 (pt) 2014-03-18
PT2107906E (pt) 2012-03-05
FR2910813A1 (fr) 2008-07-04
RS52162B (sr) 2012-08-31
TN2009000234A1 (fr) 2010-10-18
AR064550A1 (es) 2009-04-08
WO2008102075A3 (fr) 2008-12-11
ECSP099449A (es) 2009-07-31
HRP20120170T1 (hr) 2012-03-31
NO20092496L (no) 2009-07-23
HK1138189A1 (en) 2010-08-20
CA2672716A1 (fr) 2008-08-28
CA2672716C (fr) 2013-05-28
CL2007003846A1 (es) 2009-01-23
SI2107906T1 (sl) 2012-03-30

Similar Documents

Publication Publication Date Title
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
CL2007003827A1 (es) Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
CR7261A (es) Derivados de diarilcicloalquilo, procedimiento para su preparacion y su utilizacion como agentes activadores del ppar
ECSP088593A (es) 5-(arilsulfonil)-pirazolopiperidinas
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CR10165A (es) "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión"
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
ECSP088293A (es) Inhibidores de gamma secretasa, de sulfonamido n-cíclico puenteado
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
GT200700032A (es) Utilización de la agomelatina para la obtención de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada.
CR9385A (es) Agente preventivo o terapeutico para el desorden de la depresion o la ansiedad
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
GT200900168A (es) Nueva utilizacion terapeutica para el tratamiento de las leucemias
NI200900073A (es) Compuestos de carbamato para su uso en el tratamiento de la depresión.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
UY29817A1 (es) Nuevos compuestos de azetidina, composiciones farmacéuticas que los contienen, procesos de preparación y uso terapéutico de los mismos.
PA8657701A1 (es) Derivado de quinolina, su uso, preparacion y medicamento que lo contiene